NEW YORK, July 10, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. and its wholly-owned subsidiary, Forest Laboratories Holdings, Ltd. (collectively, “Forest”), and H. Lundbeck A/S (“Lundbeck”) announced today that they have entered into a settlement agreement with Sun Pharmaceutical Industries Ltd. (“Sun Pharma”, a reference that includes its 100% subsidiaries) and Caraco Pharmaceutical Laboratories, Ltd. (“Caraco”), regarding pending patent infringement disputes regarding U.S. Patent Re. No. 34,712, U.S. Patent No. 6,916,941, and U.S. Patent No. 7,420,069, which were licensed to Forest by H. Lundbeck A/S on an exclusive basis in the United States. These patents are listed in the U.S. Food and Drug Administration’s Orange Book for Forest’s LEXAPRO(R) brand escitalopram oxalate tablet products.
(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO)
Pursuant to the terms of the settlement agreement with Sun Pharma and Caraco, and subject to review of the settlement terms by the U.S. Federal Trade Commission:
Forest and Lundbeck will reimburse certain of Caraco’s legal costs in connection with these patent litigations.
About Forest Laboratories
Forest Laboratories is a U.S.-based pharmaceutical company with a long track record of building partnerships and developing and marketing products that make a positive difference in people’s lives. In addition to its well-established franchises in therapeutic areas of the central nervous and cardiovascular systems, Forest’s current pipeline includes product candidates in all stages of development and across a wide range of therapeutic areas. The company is headquartered in New York, NY. To learn more about Forest Laboratories, visit www.FRX.com.
Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories’ Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and any subsequent SEC filings.
CONTACT: Frank J. Murdolo, Vice President - Investor Relations, of Forest
Laboratories, Inc., +1-212-224-6714, or Frank.Murdolo@frx.com
Web site: http://www.frx.com/
Company News On-Call: http://www.prnewswire.com/comp/329163.html
